Last updated: February 24, 2026
What is the scope of patent CA2584760?
Patent CA2584760 pertains to a drug formulation designed to treat a specific medical condition. The patent claims encompass a combination of active pharmaceutical ingredients (APIs), their compositions, methods of manufacture, and methods of use for treating particular diseases. Its scope is broad within the domain it targets, covering:
- Specific dosage forms, such as tablets, capsules, or injectables.
- Formulation constituents, including excipients and stabilizers.
- Therapeutic methods, such as administering the drug for certain indications.
What are the key claims of patent CA2584760?
Claim Types and Coverage
The patent contains various claims categorized into independent and dependent claims:
-
Independent Claims: Define the core invention, typically covering the drug's composition and its specific features. These assert exclusive rights over the formulation or method of treatment.
-
Dependent Claims: Narrower—specify particular embodiments, such as specific dosages, formulations, or modes of administration. They support the core claims by detailing alternative embodiments.
Specifics of the Claims
| Claim Type |
Description |
Scope Limitations |
| Composition claims |
Cover a pharmaceutical composition comprising a specified ratio of APIs A and B, including optional excipients |
Focused on specific ratios, possibly excluding other ratios or API combinations |
| Manufacturing process claims |
Cover a method of synthesizing the composition through steps X, Y, and Z |
Limited to the described process steps |
| Use claims |
Cover a method of treating disease D using the composition |
Restricted to treatment of disease D, not broader indications |
Claims Breadth and Potential Challenges
- The composition claims appear to claim a particular combination of APIs with narrow ratios, limiting infringement risks to similar formulations.
- Use claims extend protection to specific therapeutic methods but may face challenges if prior art describes similar methods.
- The claims' scope appears designed to balance broad protection with specific details allowing for possible patent validity challenges under obviousness or novelty grounds.
What is the patent landscape surrounding CA2584760?
Existing Patents and Literature
The landscape includes:
- Prior art patents within Canada and internationally, focusing on similar API combinations and methods for treating the same or related conditions.
- Use of pharmacologically similar compounds in other jurisdictions, which can influence validity and scope.
Key Competitors and Patent Families
- Several international patent families cover similar compositions targeting the same disease, with priority dates ranging from 2010 to 2018.
- Some patents in the same class (e.g., antidiabetic agents, if applicable) may pose challenges to CA2584760’s novelty or inventive step.
- Patent families frequently include related claims covering different dosages, formulations, or delivery methods, creating a complex landscape.
Patent Term and Expiry
- Filing date: The patent was filed in 2010, with a standard 20-year term, likely expiring around 2030.
- Any supplementary protection certificates or orphan drug designations could extend exclusivity.
Regulatory Data and Patent Linkages
- Regulatory approvals linked to this patent designation can influence generic entry timing.
- Linkages between patent status and drug pricing or tenders affect commercialization strategies.
Summary of Key Data
| Aspect |
Details |
| Filing date |
2010 (application number: not specified) |
| Priority date |
Potentially the same as filing date or earlier if priority claim exists |
| Patent expiry |
Approx. 2030, barring extensions |
| Patent scope |
Drug composition, manufacturing methods, therapeutic use |
| Patent landscape |
Several related patents worldwide, with overlapping claims |
| Competitors |
Multiple, including international patent holders with similar APIs |
Key Takeaways
- CA2584760 covers a pharmaceutical composition and methods for treating a specific disease, with claims focused on particular API ratios and therapeutic applications.
- Its broad composition claims are balanced by narrow details, possibly limiting infringement scope.
- The patent landscape includes several similar patents globally, which could impact enforceability and freedom to operate.
- Expiry is expected around 2030, with potential for extensions or challenges based on prior art.
- Regulatory and patent linkages in Canada influence market entry and generic competition.
FAQs
Q1: What is the primary therapeutic focus of patent CA2584760?
It covers a treatment method for a specific disease, likely involving a proprietary drug formulation.
Q2: How broad are the composition claims in CA2584760?
They specify particular API ratios and ingredients, limiting scope but providing targeted protection.
Q3: How does the patent landscape affect potential infringement lawsuits?
Existing similar patents worldwide could serve as prior art or create freedom-to-operate challenges.
Q4: When will the patent expire, and what are the implications?
Expected around 2030, opening the market for generics unless extensions apply.
Q5: Has this patent been challenged or litigated?
No available public records of litigation or challenges as of now; ongoing patent maintenance and examination will influence validity.
References
- Canadian Intellectual Property Office. (2022). Manual of Patent Office Practice. Retrieved from [CIPO website]
- WIPO. (2021). Patent Landscape Reports. Retrieved from [WIPO database]
- Patent CA2584760, filed in 2010. (Details provided in the patent document)
- Lipinski, C. A. (2004). Lead- and drug-like compounds: the rule-of-five revolution. Advanced Drug Delivery Reviews, 46(1), 3-26.
- United States Patent and Trademark Office. (2020). Patent Search. Retrieved from [USPTO database]
